Boards of directors: What do medtech entrepreneurs need to know?

Gallery

This gallery contains 1 photo.

While working with emerging medtech companies, I usually report directly to the CEO (usually an entrepreneur) and in turn, the board of directors. This got me thinking: (i) What are the responsibilities and duties of board directors? and (ii) What … Continue reading

Medtech entrepreneurs: What do investors want?

Gallery

This gallery contains 1 photo.

This week I attended the 15th MedTech Investing Europe conference, in London. Around 35 fascinating companies presented or attended, looking for levels of investment ranging from £500k to £15 million. Two of the panels concentrated on investors – both VC … Continue reading

Corporate VCs v VC firms: Are your investors aligned?

Gallery

This gallery contains 3 photos.

Corporate venture capital “is the investment of corporate funds directly in external start-up companies” (Wikipedia). As a medtech entrepreneur raising funds, you should know about them. They are an extremely valuable source of VC funding for your company. But they … Continue reading

What Every Medtech Entrepreneur Should Know About VCs

Gallery

This gallery contains 3 photos.

You’re an entrepreneur. You’re developing a new medtech application that’s going to take over the world and make life better for thousands, maybe millions of people. You’re idea is great, you’ve had some seed funding, perhaps a little money from … Continue reading

When Neopolitan Beats Vanilla: What Specialist Medtech Investors can Learn from Generalists

Gallery

This gallery contains 4 photos.

Many investors are specialists. Indeed, specialism in something is usually the way to excel at whatever is your choosing. But can it lead to challenges (e.g. tunnel vision), and is there a way to overcome the specialist’s curse? I’ve spent … Continue reading

8 Insights from Medtech Entrepreneurs at BioTrinity, UK

Gallery

This gallery contains 3 photos.

This week saw the BioTrinity conference in Newbury, UK, organised by OBN. It’s a fairly big date on the UK life sciences scene, with over 800 attendees, and impressively, a very healthy VC turn-out from London, Europe and even the … Continue reading